The American pharmaceuticals group JOHNSON AND JOHNSON is well into discussions for the purchase of INVERNESS MEDICAL TECHNOLOGY, specialised in glycaemia tests for diabetics for the sum of $1.3 billion through a share swap. According to the terms of the negotiation, INVERNESS MEDICAL TECHNOLOGY would break away from its activities not linked to diabetes to form a new enterprise quoted on the Stock Exchange